

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

Table 1

Comparison of RDP58 administration times on EAE disease progression^a

Treatment	Incidence ^b	Mean day of onset ^c (mean \pm S.E.M.)	Disease Index ^d (mean \pm S.E.M.)	Mean maximum severity ^c (mean \pm S.E.M.)
Mannitol	5/5	11.4 \pm 0.2	1.7 \pm 0.3	2.6 \pm 0.4
RDP58 (d 1)	5/5	13.6 \pm 0.2*	0.3 \pm 0.2*	1.2 \pm 0.2
RDP58 (d 4)	3/5	12.7 \pm 0.7	0.3 \pm 0.1*	1.0 \pm 0.4
RDP58 (d 7)	2/5	12.0 \pm 0.0	0.1 \pm 0.1*	0.4 \pm 0.2*
RDP58 (d 10)	0/5*	-	0.0 \pm 0.0*	0.0 \pm 0.0*

^a Lewis rats immunized with MBP+CFA (day 0) and treated with 150 μ g RDP58 (0.81 mg/kg) by icv injection as described in Materials and Methods.

^b Parameter of disease evaluated by Fisher's exact test (*P<0.01).

^c Parameter of disease evaluated by Kruskal-Wallis test (*P<0.05 with post hoc analysis using Dunn's multiple comparison test).

^d Parameter of disease evaluated by ANOVA (*P<0.01 with post hoc analysis using Dunnett's multiple comparison test).

FIGURE 7